Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002474:Cell-Free System; D002478:Cells, Cultured; D055598:Chemical Phenomena; D002621:Chemistry; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D017245:Foscarnet; D006566:Herpesviridae Infections / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D019384:Nucleic Acid Synthesis Inhibitors; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors; D013329:Structure-Activity Relationship; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; D012321:DNA-Directed RNA Polymerases; D010746:Phosphonoacetic Acid